Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
Does the extent of ENE affect your recommendation for concurrent chemotherapy in HPV+ OPSCC patients planned for adjuvant RT?
Does the ENE of 1 mm or less versus >1 mm as in ECOG 3311 affect your decision?
Answer from: Radiation Oncologist at Academic Institution
I'm wary of de-escalating treatment without phase 3 data supporting that decision. So any ECE, I treat with 66 Gy and concurrent chemo.
Sign in or Register to read more
19938
Related Questions
What are your top takeaways in Head & Neck Cancers from ASTRO 2024?
How are you integrating the findings from KEYNOTE-689 into daily practice?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
What is the role of radiation therapy for Kimura's disease of the parotid and neck?
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
What is the role for chemo immunotherapy in the up front setting in non-metastatic head & neck cancer outside of clinical trials?
How would you approach a patient with a carotid body tumor and metastasis to the cervical lymph node?
What is the role of adjuvant RT for metastatic RCC to the thyroid resected with high-risk features?